Skip to main content
SpringerLink
Log in

“Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Purpose

Approximately 25 % of cases of clinically active acromegaly cases treated in our academic center between 1996 and 2000, were diagnosed in patients who had elevated plasma IGF-1 levels, but apparently “normal” 24-h mean plasma GH levels. The current study served to update the data for patients with acromegaly referred to our facility, after increasing awareness of this “normal” GH subpopulation throughout the medical community.

Methods

A retrospective chart review was conducted on 157 patients with acromegaly who underwent resection of a confirmed somatotroph pituitary adenoma at the University of Michigan Health System between the dates of 1 Jan 2001 to 23 Sept 2015.

Results

Overall prevalence of acromegalic patients with “normal” GH levels, defined as GH <4.7 ng/mL, was 31 %. Over time, the percentage of patients with “normal” GH at diagnosis did not decline: 26 % from 2001 to 2005, 19 % from 2006 to 2010, and 47 % from 2011 to 2015. Mean pituitary tumor size was 1.8 ± 0.1 cm for the group with elevated GH, and 1.2 ± 0.1 cm for the group with “normal” GH (p < 0.001). Percent microadenomas was higher in a group with “normal” GH as compared to those with elevated GH (48 vs. 12 %, p < 0.001), and tumors >2 cm in the maximal diameter were encountered more frequently in the group with elevated GH (43 vs. 14 %, p < 0.001).

Conclusions

Our data show that a substantial percentage of patients with clinical acromegaly have “normal” GH, and therefore strengthens the growing body of evidence which supports the leading role of IGF-1 levels in diagnostic evaluation. At the present time, questions about the natural course of “micromegaly” and treatment benefits compared to the subpopulation with elevated GH levels remain unanswered, but research continues to build on our understanding of the heterogeneous population of individuals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL (2002) Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab 87(8):3537–3542

    Article  CAS  PubMed  Google Scholar 

  2. Bajuk Studen K, Barkan A (2008) Assessment of the magnitude of growth hormone hypersecretion in active acromegaly: reliability of different sampling models. J Clin Endocrinol Metab 93(2):491–496

    Article  PubMed  Google Scholar 

  3. Holdaway IM, Rajasoorya C (1999) Epidemiology of acromegaly. Pituitary 2(1):29–41

    Article  CAS  PubMed  Google Scholar 

  4. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R (1980) Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol 12(1):71–79

    Article  CAS  Google Scholar 

  5. Bengtsson BA, Edén S, Ernest I, Odén A, Sjögren B (1988) Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand 223(4):327–335

    Article  CAS  PubMed  Google Scholar 

  6. Burton T, Le Nestour E, Neary M, Ludlam WH (2016) Incidence and prevalence of acromegaly in a large US health plan database. Pituitary 19(3):262–267

    Article  PubMed  PubMed Central  Google Scholar 

  7. Davidoff LM (1926) Studies in acromegaly III. The anamnesis and symptomatology in one hundred cases. Endocrinology 10:445–540

    Article  Google Scholar 

  8. Rivoal O, Brezin AP, Feldman-Billard S, Luton JP (2000) Goldmann perimetry in acromegaly: a survey of 307 cases from 1951 through 1996. Ophthalmology 107(5):991–997

    Article  CAS  PubMed  Google Scholar 

  9. Clemmons DR, Van Wyk JJ, Ridgway EC, Kliman B, Kjellberg RN, Underwood LE (1979) Evaluation of acromegaly by radioimmunoassay of somatomedin-C. N Engl J Med 301(21):1138–1142

    Article  CAS  PubMed  Google Scholar 

  10. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU (2010) Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol 72(2):203–208

    Article  Google Scholar 

  11. Ribeiro-Oliveira A, Faje AT, Barkan AL (2011) Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol 164(1):17–22

    Article  CAS  PubMed  Google Scholar 

  12. Ribeiro-Oliveira A Jr, Abrantes MM, Barkan AL (2013) Complex rhythmicity and age dependence of growth hormone secretion are preserved in patients with acromegaly: further evidence for a present hypothalamic control of pituitary somatotropinomas. J Clin Endocrinol Metab 98(7):2959–2966

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM, Snyder PJ (2011) Clinically silent somatotroph adenomas are common. Eur J Endocrinol 165(1):39–44

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Faje AT, Barkan AL (2010) Basal, but not pulsatile, growth hormone secretion determines the ambient circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 95(5):2486–2491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lindholm J, Giwercman B, Giwercman A, Astrup J, Bjerre P, Skakkebaek NE (1987) Investigation of the criteria for assessing the outcome of treatment in acromegaly. Clin Endocrinol 27(5):553–562

    Article  CAS  Google Scholar 

  16. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426

    CAS  PubMed  Google Scholar 

  17. Damjanovic SS, Nescovic AN, Petakov MS, Popovic V, Macut D, Vukojevic P, Joksimovic MM (2005) Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clin Endocrinol 62(4):410–417

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Metabolism, Endocrinology, and Diabetes, Internal Medicine Department, University of Michigan, 24 Frank Lloyd Wright Drive, G-1500, P.O. Box 482, Ann Arbor, MI, 48106, USA

    Laura B. Butz, William F. Chandler & Ariel L. Barkan

  2. Department of Neurosurgery and the Pituitary and Neuroendocrine Center, University of Michigan, Ann Arbor, MI, USA

    Stephen E. Sullivan, William F. Chandler & Ariel L. Barkan

Authors
  1. Laura B. Butz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen E. Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William F. Chandler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ariel L. Barkan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ariel L. Barkan.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Butz, L.B., Sullivan, S.E., Chandler, W.F. et al. “Micromegaly”: an update on the prevalence of acromegaly with apparently normal GH secretion in the modern era. Pituitary 19, 547–551 (2016). https://doi.org/10.1007/s11102-016-0735-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-016-0735-0

Keywords

Search

Navigation